I am starting to now believe - rather than hope, that all 4 of the current phase 2 trials will be successful.
Similar ailments treated by the same drug.
Efficacy is the only real variant.
And then phase 3 - with this science? With this management team - I believe they will be successul too (albeit with the fact that Neuren themselves have not as yet got a drug past phase 3).
They must have learnt something with Trofinetide regarding that! And they have plenty of cash to hire/contract the right people to do the job.
Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.09 |
Change
0.235(1.83%) |
Mkt cap ! $1.635B | |||
| Open | High | Low | Value | Volume |
| $13.15 | $13.37 | $12.92 | $4.838M | 368.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 25 | $13.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.10 | 1006 | 6 |
View Market Depth
| Last trade - 13.07pm 18/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |